Drug Trial Radar · NCT02015260
A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
Last checked: Nov 19, 2026Latest source record: May 3, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
299
Actual
Start
Sep 2001
Primary completion
May 2003
Study completion May 2003
Sponsor
- Lead sponsor
- University of AberdeenAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Kyowa Kirin Co., Ltd.; Erasmus Medical Center
- First posted
- Dec 19, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Objective To assess the efficacy of the topical application of Nitric Oxide, delivered using acidified nitrite. Design Multicentre, randomized, controlled, dose ranging trial. A control arm and three doses of acidified nitrite applied topically for 12 weeks with a further 12 weeks of follow up. Setting The trial setting was in European genitourinary medicine clinics Participants Male and female volunteers over 18 years of age with between 2 and 50 ano-genital warts, 328 were screened for eligibility and 299 subjects from 40 centres were randomised. Exclusions Pregnancy; concomitant Sexually Transmitted Disease; internal warts requiring treatment other than surgery /laser; diabetes ; Human Immunodeficiency Virus-positive, immunosuppressed and/or using immunosuppressive therapies; drug abuse. interventions compared * Control Placebo nitrite cream and placebo citric acid cream twice daily * A) 3% sodium nitrite + 4.5% citric acid creams twice daily * B) 6% sodium nitrite + 9% citric acid creams once daily * C) 6% sodium nitrite + 9% citric acid creams twice daily Outcomes * Primary proportion of patients with complete clearance of target warts Secondary * Time to clearance * Wart area * Wart count * Patient and investigator assessment of efficacy * Safety * Tolerability * Adherence
Conditions
- Anogenital Warts
- Condylomata Acuminata
Interventions
Topical NODrug
Varying doses of sodium nitrite and citric acid co-applied to warts
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients with complete clearance of target warts in Intention to treat (ITT) populationTime frame: 24 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.